



IBA Closes Agreement to Divest PharmaLogic PET Services of Montreal Company Assets

Louvain-la-Neuve, Belgium, March 17, 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the closing of an agreement for the sale to a private equity firm of the assets of PharmaLogic PET Services of Montreal Company, a Canadian company in which IBA owns a substantial but minority interest.

Approximately 85 per cent of the price has been paid to PharmaLogic at closing and the rest will be released after a two year period. Payments will then be distributed as dividends to PharmaLogic's shareholders, including IBA.

IBA expects a net total cash inflow in dividend from this sale of about EUR 7.7 million. The transactions will have no impact on 2013 accounts, but should positively impact IBA's 2014 net results by approximately EUR 3.5 million.

Olivier Legrain, Chief Executive Officer of IBA, commented: *"We are delighted to have completed, together with our Canadian partners, the disposal of the assets of PharmaLogic in line with our strategy to divest non-core assets in order to focus IBA on proton therapy and associated technologies."*

- Ends -

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

Press release |

Regulated information



IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

IBA

Jean-Marc Bothy

Chief Financial Officer

+32 10 47 58 90

investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 47 58 90

communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal,

Ivar Milligan, Jessica Hodgson

+44 (0)20 3709 5700

IBA@consilium-comms.com